Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next?

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI)’s share price shot up 3% on Tuesday . The company traded as high as $1.05 and last traded at $1.03. 47,587 shares traded hands during trading, a decline of 89% from the average session volume of 418,306 shares. The stock had previously closed at $1.00.

Wall Street Analysts Forecast Growth

SCNI has been the topic of several research reports. Wall Street Zen raised Scinai Immunotherapeutics to a “sell” rating in a report on Saturday, August 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Scinai Immunotherapeutics Price Performance

The company has a 50-day moving average of $1.23 and a 200 day moving average of $1.75. The company has a market cap of $3.28 million, a PE ratio of -0.11 and a beta of 1.65.

Institutional Trading of Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its position in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent filing with the Securities & Exchange Commission. 58.41% of the stock is owned by hedge funds and other institutional investors.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.